Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study
| Autor: | Samkit Shah, Mohan Kale, Varsha Jamale, Balkrishna Nikam, Dhananjay K Chavan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Visual analogue scale Dermatology Severity of Illness Index Gastroenterology law.invention Acitretin 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Psoriasis Area and Severity Index Internal medicine Psoriasis medicine Humans Prospective Studies Adverse effect Body surface area business.industry General Medicine medicine.disease Hospitals Methotrexate Treatment Outcome 030220 oncology & carcinogenesis Cyclosporine Quality of Life business medicine.drug |
| Zdroj: | Dermatologic Therapy. 34 |
| ISSN: | 1529-8019 1396-0296 |
| DOI: | 10.1111/dth.14650 |
| Popis: | Palmoplantar psoriasis (PPP) is a variant of psoriasis which affects only 5% body surface area, but has a devastating impact on affected individual's quality of life. There are few studies assessing efficacy of individual drugs, and few comparative studies of efficacy of two drugs in the literature, however randomized control trial comparing all three drugs against each other has not been done. A total of 75 patients of PPP were enrolled for study and randomly divided into three groups A, B, C of 25 each and assigned for treatment with cyclosporine (CSA) (2.5-5 mg/kg/d), methotrexate (MTX)(7.5-15 mg/week), and acitretin (ACT) (25-50 mg/d), respectively. Modified psoriasis area and severity index (PASI), psoriasis severity scale, visual analogue scale, physician global assessment, and PPQOL were used for monitoring response to therapy and improvement in quality of life up to end of study, and thereafter monthly follow-up was done to find duration of remission for next 90 days. Side effects if any were recorded. There was a statistically significant difference in modified PASI for CSA, MTX, and ACT. The mean modified PASI at baseline was 12.8 ± 4.8 for CSA, 12.57 ± 3.8 for MTX, and 11.92 ± 3.28 for ACT (P = .75). Mean modified PASI reduced to 2.91 ± 1.8 for CSA, 6.57 ± 2.2 for MTX, and 4.7 ± 2.2 for ACT at week 5 (P = |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|